Mirati Therapeutics, Inc., a commercial stage biotechnology company, announced the Journal of Clinical Oncology published in a Rapid Communication data indicating adagrasib, a potent and selective...
Merck, known as MSD outside of the United States and Canada, announced results from the Phase 3 KEYNOTE-966 trial investigating KEYTRUDA, Merck’s anti-PD-1 therapy,...
AstraZeneca’s IMFINZI (durvalumab) has been approved in the US for the treatment of adult patients with locally advanced or metastatic biliary tract cancer (BTC)...
